This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: Gpcr Therapeutics, Inc.. Active years: 2020-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2024
Title: Innovations by DongSeung Seen in Cancer Treatment
Introduction
DongSeung Seen is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer research through his innovative inventions. With a total of 2 patents, Seen is recognized for his work on G protein-coupled receptor (GPCR) heteromers.
Latest Patents
His latest patents focus on GPCR heteromer inhibitors and their applications in cancer therapy. These inventions relate to inhibitors of CXC receptor 4 (CXCR4)-G protein-coupled receptor (GPCR) heteromers associated with various cancers. Specifically, his work addresses the functional heteromer formed between CXCR4 and other GPCRs, which enhances signaling when co-stimulated with specific agonists. The inventions also include inhibitors that target the interacting GPCR partner of the CXCR4-GPCR heteromer, providing potential diagnostic and therapeutic applications for cancer treatment.
Career Highlights
DongSeung Seen is currently associated with GPCR Therapeutics, Inc., where he continues to advance his research and innovations. His work has garnered attention in the scientific community for its potential impact on cancer therapies.
Collaborations
He collaborates with notable colleagues, including Eunhee Kim and Jae-Yeon Jeong, who contribute to his research endeavors.
Conclusion
DongSeung Seen's innovative work in developing GPCR heteromer inhibitors represents a significant advancement in cancer treatment. His contributions are paving the way for new therapeutic strategies in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile